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Neuroimmunology: 
An expanding frontier in 21st century Neurology
1,2 3
Mohammad Saeed MD, DABIM (Rheumatology) , Arsalan Ahmad MD(Neurology)
The recent discovery of functional lymphatic vessels lining the dural sinuses shattered the long held view of the 
1
absence of CNS lymphatic vas culature and provided solid neuroanatomical ground for Neuroimmunology . 
Moreover, it has been shown that there is the presence of what is known as the inﬂammatory reﬂex. This is mediated 
by sensory neurons and transmitted directly to immune cells such as the macro phages and T-cells via specialized 
2
cholinergic receptors . These ﬁndings demonstrate a strong interaction between the nervous and immune systems.
One of the major proteins that contribute to the pathogenesis of Parkinson's disease (PD) is alpha-synuclein (aSyn). 
Surprisingly, alpha-synuclein pathogenic inclusions were recently shown spread to the brain from the gastro 
3
intestinal tract (GIT) in a manner similar to prion diseases . With the vagus nerve tracking through the GIT, it plays a 
key role in the interaction of the brain with the immune system. Inﬂammation in the GIT leads to over expression and 
aggregation of aSyn in the enteric nervous system and spreads to the vagal dorsal motor nucleus in the brainstem 
4
via the nerve . GIT micro bio me has been shown to be a key component of this spread by release of mediators 
3 5
affecting inﬂammation .The prion-like mechanism of spread has previously been demonstrated for ALS as well , 
1 1
where mutant SOD  converts normal mitochondrial SOD  into an abnormal protein leading to mitochondrial 
5
aggregations and dys function . 
In the brain, the astrocytes maintain the blood-brain-barried (BBB) while the micro glia directly contribute to immune 
defense mechanisms. Alzheimer's disease (AD) is characterized by plaques and neuro ﬁbrillary tangles (NFT), the 
latter being composed predominantly of the misfolded protein Tau. In a mouse model it was shown that antibodies 
directed against Tau prevented the spread of NFTs. Modulation of the Fc portion of the antibodies led to absence of 
binding to micro glia with consequent reduction of release of inﬂammatory mediators and ensuing 
6
neuroinﬂammation . Thus such a strategy could have immune-therapeutic effects on AD.
Multiple sclerosis (MS) has seen rapid immun other apeutic advances with the advent of monoclonal antibodies. 
Nataluzimab (an integrin inhibitor preventing lymphocyte extra vasation) and Rituximab (B-cell inhibitor) showed 
remarkable success in disease management. Recently Ocrelizumab, a humanized form of Rituximab, was recently 
7
approved by FDA for treatment of Primary progressive MS . Teriﬂunamide, a hepatic metabolite of an old anti-
8
rheumatic drug - Leﬂunomide, was also approved by FDA for MS . In resource limited countries such as Pakistan, 
Leﬂunomide has been successfully used for treatment of MS, though formal studies to assess its efﬁcacy are 
currently lacking. 
Several neuropsychiatric syndromes and immune encephalitis are now yielding to the power of Neuroimmunology 
and being routinely diagnosed to be mediated by antibodies such as the anit-GABA, anti-NMDA, anti-VGKC 
(CASPR2& LGI1) and the more familiar dsDNA. This has opened doors to treatments which were previously 
impossible. Now chemical or biological immunomodulators are helping to bring such vague diseases under 
excellent clinical control. Furthermore the recent introduction of onco-neural antibodies is an added tool in the 
diagnosis of previously elusive paraneoplastic neurological syndromes.
These pathobiologic advances, combined with immunotherapeutics and a broad range of available antibody tests 
has made Neuroimmunology a major diagnostic and therapeutic ﬁeld of immense clinical signiﬁcance. 
Date of submission: May 22, 2017   Date of revision: June 29, 2017   Date of acceptance: June, 2017
1
Consultant Rheumatologist, Medlife Clinic, 
2
South City Hospital, Karachi, 
3
Professor of Neurology, Shifa International Hospital, Shifa Tameer-e-Millat University, Islamabad
Corresponding to: Arsalan Ahmad MD(Neurology), Shifa International Hospital, Shifa Tameer-e-Millat University, Islamabad email: arsalanahmad65@gmail.com
 
Conﬂict of interest: Author declares no conﬂict of interest.
Funding disclosure: Nil
Author's contribution:
Mohammad Saeed; concept, data collection, data analysis, manuscript writing, manuscript review
Arsalan Ahmed; data collection, data analysis, manuscript writing, manuscript review
0 2
1. Louveau A, Smirnov I, Keyes TJ, et al. 
Structural and functionalfeatures of central 
nervous system lymphatic vessels. Nature. 
2015 Jul16;523(7560):337-41. PubMed 
PMID: 26030524
2. Pavlov VA, Tracey KJ.Neural circuitry and 
immunity.Immunol Res. 2015 Dec;63(1-
3):38-57. PubMed PMID: 26512000.
      3.   Sampson TR, Debelius JW, Thron T, et al.   
            Gut Microbiota Regulate Motor Deﬁcits and  
            Neuroinﬂammation in a Model of Parkinson's 
            Disease. Cell. 2016 Dec 1;167(6):1469-1480
            e12. PubMed 27912057.
4. Houser MC, Tansey MG. The gut-brain axis: 
is intestinal inﬂammation a silent driver of 
Parkinson's disease pathogenesis? NPJ 
Parkinsons Dis. 2017 Jan 11;3:3. PubMed 
PMID: 28649603.
5. Deng HX, Shi Y, Furukawa Y, et al. 
Conversion to the amyotrophic lateral 
sclerosis phenotype is associated with 
intermolecular linked insoluble aggregates of 
SOD1 in mitochondria. ProcNatlAcadSci U S 
      6. Lee SH, Le Pichon CE, Adolfsson O, et al. 
             Antibody-Mediated Targeting of Tau In Vivo 
             Does Not Require Effector Function and 
             Microglial Engagement. Cell Rep. 2016 Aug 
             9;16(6):1690-1700. PubMed PMID: 
             27475227.
7. Montalban X, Hauser SL, Kappos L, et al. 
Ocrelizumab versus placebo in primary 
progressive multiple sclerosis.N Engl J Med 
2017;376:209-220. 
8. O'Connor P, Wolinsky JS, Confavreux C, et al. 
Randomized trial of oral teriﬂunomide for 
relapsingmultiple sclerosis. New Engl J Med 
2011;365:1293–1303.
P A K I S T A N  J O U R N A L O F N E U R O L O G I C A L S C I E N C E S V O L . 1 2 ( )  -  2 0 1 73 J U L S E P
REFERENCES:       A. 2006 May 2;103(18):7142-7. PubMed 
PMID: 16636275.
5. Deng HX, Shi Y, Furukawa Y, et al. 
Conversion to the amyotrophic lateral 
sclerosis phenotype is associated with 
intermolecular linked insoluble aggregates of 
SOD1 in mitochondria. ProcNatlAcadSci U S 
A. 2006 May 2;103(18):7142-7. PubMed 
PMID: 16636275.
